首页 | 本学科首页   官方微博 | 高级检索  
检索        


Changing results of HLA-identical sibling bone marrow transplantation in patients with haematological malignancy during the period 1981–1990
Authors:K Atkinson  G Marshall  J C Biggs  F Wilson  A J Concannon  S Young  A J Dodds  M Ashby  S Milliken  G Morgan  K Downs  J Harkness
Institution:Associate Professor, School of Medicine, Senior Staff Specialist, Department of Haematology, Sydney, NSW;Data Collector, Department of Haematology, St Vincent's Hospital, Sydney, NSW.;Associate Professor and Director of Haematology, St Vincent's Hospital, Sydney, NSW.;Nurse Unit Manager, Department of Haematology, St Vincent's Hospital, Sydney, NSW.;Senior Staff Specialist, Department of Haematology, St Vincent's Hospital, Sydney, NSW.;Nurse Unit Manager, Department of Haematology, St Vincent's Hospital, Sydney, NSW.;Senior Staff Specialist, Department of Haematology, St Vincent's Hospital, Sydney, NSW.;Data Collector, Department of Haematology, St Vincent's Hospital, Sydney, NSW.;Staff Specialist, Department of Microbiology, St Vincent's Hospital, Sydney, NSW.;Staff Specialist, Radiation Oncologist, Department of Oncology, St Vincent's Hospital, Sydney, NSW.;Data Manager, Department of Haematology, St Vincent's Hospital, Sydney, NSW;Director, Department of Microbiology, St Vincent's Hospital, Sydney, NSW.
Abstract::During the years 1981-90 inclusive 227 patients with haematological malignancy received an HLA-identical sibling first transplant at St Vincent's Hospital, Sydney. Recipients with acute leukaemia in first remission or chronic myeloid leukaemia in first chronic phase were analysed as good risk, and those beyond these stages, as poor risk patients. Good risk patients transplanted in the years 1986-90 ( n = 52) showed improved actuarial survival (74%) compared to those ( n = 58) transplanted during 1981-85 (37%, p = 0.01). There was a suggestion that leukaemia-free survival was also improved in those transplanted during the later time period (62% versus 36%, p = 0.07). In contrast, poor risk patients transplanted during 1986-90 ( n =55) appeared to have worse leukaemia-free survival (15%) compared to those transplanted during 1981-85 ( n = 62) (22%, p = 0.09). The incidence of acute graft-versus-host disease (GVHD) grades I-IV in all patients was 94% in those transplanted during 1981-85 ( n =120) and 86% in those transplanted during 1986-90 ( n =107) ( p = 0.002). The incidence of acute GVHD grades II-IV was 37% during 1981-83, 20% during 1984-86, and 28% during 1987-90 ( p = 0.1). The decrease in incidence and severity of acute GVHD correlated with the introduction of the cyclosporin/short methotrexate regimen in our practice. The incidence of cytomegalovirus (CMV) pneumonitis was 18% in 1981-85, and 11% in 1986-90 ( p = 0.09). In 1989 and 1990 no cases of CMV pneumonitis occurred. The decrease in incidence of CMV pneumonitis correlated with the introduction of prophylactic ganciclovir. The reduction of the transplant-related complications acute GVHD and CMV pneumonitis has resulted in improved survival for good risk patients, but not for bad risk patients. (Aust NZ J Med 1993; 23: 181–186.)
Keywords:Bone marrow transplantation  leukaemia  graft-versus-host disease  cytomegalovirus infection  cyclosporin  ganciclovir
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号